

RESPONDER CELLS: RAT SPLEEN CELLS
STIMULATOR CELLS: HUMAN HEPATOCYTES

SPLEEN(S): SPLEEN CELLS FROM RATS
TREATED WITH SALINE WHEN THEY WERE
FETUSES.

HEP: IRRADIATED HUMAN HEPATOCYTES.

SPLEEN(IU): SPLEEN CELLS FROM RATS
TOLERIZED BY INTRAUTERINE INJECTION OF
HUMAN HEPATOCYTE LYSATES.

SPLEEN(IU/IS): SPLEEN CELLS FROM RAT
TOLERIZED BY INTRAUTERINE INJECTION OF
HUMAN HEPATOCYTE LYSATES FOLLOWED
BY INTRASPLENIC TRANSPLANTATION OF
HUMAN HEPATOCYTES AFTER BIRTH.

FIG.1

20230718.032902

1 2 3 4 5

FIG.2

0930781-032802




FIG.3



FIG. 4A



FIG. 4B




FIG. 4C



FIG. 4D

09930781.032802




FIG.5




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 6D




FIG.7

Time course of human albumin and HBV expression

Anti Human Albumin

Anti Hepatitis B Surface Antigen

1 week




FIG.8A




FIG.8B

6 weeks




FIG.8C




FIG.8D

09030781-032802

09930781.032802
2082ED T870E66D

14 weeks




FIG.8E




FIG.8F

09930781.032802
208220"TBZ0E660

Rat CA2
Hepatocytes
Plus HBV

Anti Human Albumin



FIG.9A

Anti Hepatitis B Surface Antigen



FIG.9B

Rat CA3
Hepatocytes
alone



FIG.9C




FIG.9D

Rat CA5
HBV alone




FIG.9E




FIG.9F

Rat CA2
minus primary Ab



FIG.9G



FIG.9H

09930781.032802




FIG.10

RT-PCR Human Albumin RNA





FIG.11A

RT-PCR HBV RNA



- 1: 1 kbp ladder
- 2: Rat liver RNA
- 3: Human liver RNA
- 4: HepG2.2.15 RNA
- 5: Rat CA2 - Human hepatocytes + HBV,
1 week post
- 6: Rat CA2 - 6 weeks post
- 7: Rat CA2 - 14 weeks post

FIG.11B





FIG.12

Hepatocytes
plus HBV

1 week


FIG.13A



Hepatocytes
plus HBV

6 weeks


FIG.13B



Hepatocytes
plus HBV

14 weeks

FIG.13C




09930781.032802

Hepatocytes
plus HBV

1 week


FIG.14A



Hepatocytes
plus HBV

6 weeks


FIG.14B



Hepatocytes
plus HBV

14 weeks

FIG.14C



09930781.032802

20932ED.T840E65D




FIG. 15



FIG. 16A




FIG. 16B




FIG. 16C




FIG. 16D



FIG. 16E




FIG. 16F




FIG.17A



FIG.17B




FIG.17C




FIG.17D




FIG.18A




FIG.18B

208220.T8/0E660

09930781.032802




FIG.19A




FIG.19B

208220.T8.03660




FIG.20




Fig. 21




FIG. 22

Day 1



FIG. 23A



FIG. 23B

X125

X250




FIG. 23C




FIG. 23D

X125

X250

Day 7



FIG. 23E

X125




FIG. 23F

X250

09930781.032802

FIG. 24A



FIG. 24B



FIG. 24C



FIG. 24D



208220-TB70E660




FIG. 25

FIG. 26A

Primary human hepatocytes

6 wks 16 wks

Tolerized and
transplanted

Tolerized but not
transplanted




FIG. 26B

palb3 plasmid

100 pg 10 pg 1 pg



Arbitrary Units




FIG. 26C

FIG. 27A





FIG. 27B

09930781.032802




FIG. 28

human Albumin




FIG. 29A

BrdU




FIG. 29B

**Tolerized
with T3
no trans-
plantation**




FIG. 29C




FIG. 29D

**Tolerized
with T3
and trans-
plantation**



FIG. 29E




FIG. 29F

**Control
no T3
no trans-
plantation**

09930781.032802




FIG. 30

Time Post-HCV Inoculation (weeks)

















FIG 31

FIG. 32

Time Post-HCV Inoculation (weeks)

	4	6	8	12	16
Huh7	 +	 +	 +	 +	 +
HepG2					
PHH	 +				
PBS	 +	 -	 -	 -	 -